Prasuva 10 mg Tablet contains Prasugrel, a potent oral antiplatelet agent used to reduce the risk of thrombotic cardiovascular events in patients with acute coronary syndrome (ACS) undergoing percutaneous coronary intervention (PCI). It plays a critical role in preventing platelet aggregation, thereby lowering the incidence of serious complications such as myocardial infarction, stroke, and stent thrombosis.

Prasugrel belongs to the thienopyridine class of antiplatelet drugs and is administered as part of dual antiplatelet therapy, usually in combination with aspirin. It is specifically indicated for patients with unstable angina, non-ST-elevation myocardial infarction (NSTEMI), and ST-elevation myocardial infarction (STEMI) who are managed with primary or delayed PCI.

রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Indications

Prasuva 10 mg is indicated to reduce the rate of thrombotic cardiovascular events, including stent thrombosis, in patients with acute coronary syndrome undergoing PCI, including:

• Patients with unstable angina (UA)

• Patients with non-ST-elevation myocardial infarction (NSTEMI)

• Patients with ST-elevation myocardial infarction (STEMI) managed with primary or delayed PCI

Therapeutic Class

• Anti-platelet drugs

Pharmacology

Prasugrel is a selective inhibitor of platelet activation and aggregation. After oral administration, it is rapidly metabolized to an active metabolite that irreversibly binds to the P2Y12 ADP receptor on platelets. This binding inhibits ADP-mediated activation of the GPIIb/IIIa receptor complex, thereby preventing platelet aggregation for the lifespan of the platelet. The irreversible action provides consistent and sustained antiplatelet effects, which are essential in high-risk cardiovascular patients.

Dosage and Administration

Treatment with Prasuva 10 mg should be initiated with a single oral loading dose of 60 mg. This is followed by a maintenance dose of 10 mg once daily, taken with or without food.

• A reduced maintenance dose of 5 mg once daily should be considered for patients weighing less than 60 kg

• Prasuva should be administered in combination with aspirin (75 mg to 325 mg daily)

Dosage and duration of therapy should be determined by the treating physician based on the patient’s clinical condition and bleeding risk.

Drug Interactions

• Concomitant use with warfarin or chronic use of NSAIDs may increase the risk of bleeding

• Prasugrel may be safely co-administered with aspirin, heparin, GPIIb/IIIa inhibitors, statins, proton pump inhibitors, and H2 blockers

• Drugs that induce or inhibit cytochrome P450 enzymes do not significantly affect prasugrel activity

Contraindications

Prasuva 10 mg is contraindicated in patients with:

• Active pathological bleeding such as peptic ulcer or intracranial hemorrhage

• History of prior transient ischemic attack (TIA) or stroke

  রেজিস্টার্ড চিকিৎসকের পরামর্শ অনুযায়ী ঔষধ সেবন করুন

Adverse Effects

The most common adverse effect associated with Prasuva is bleeding. Other reported side effects include:

• Thrombotic thrombocytopenic purpura

• Headache

• Back pain

• Dyspnea

• Nausea

• Hypertension

• Bradycardia

• Skin rash

Precautions and Warnings

• Increased risk of bleeding, particularly in patients undergoing coronary artery bypass graft (CABG) surgery

• Premature discontinuation may increase the risk of stent thrombosis, myocardial infarction, and death

• Use with caution in elderly patients, especially those over 75 years of age

Use in Special Populations

• Pediatric use: Safety and efficacy have not been established

• Geriatric patients: Increased risk of fatal bleeding

• Renal impairment: No dosage adjustment required

• Hepatic impairment: No dosage adjustment required in mild to moderate impairment

• Pregnancy and lactation: Use only if potential benefit justifies potential risk

Storage Conditions

Store in a dry place, protected from light and heat. Keep out of reach of children.